Anne Roivainen profile picture
Professor of Preclinical Imaging and Drug Research


+358 40 824 3510
Kiinamyllynkatu 4-8

Areas of expertise

Molecular Imaging
Inflammation Imaging


Our group is based in Turku PET Centre, University of Turku and Turku University Hospital. Our research focuses on developing radiopharmaceuticals for the PET imaging of various inflammatory diseases.

Inflammation is a significant component of several chronic diseases involving the cardiovascular, metabolic, respiratory, gastro-intestinal, musculoskeletal and nervous systems. Positron emission tomography (PET) with targeted probes enables evaluation of the molecular and cellular pathophysiological mechanisms of diseases (i.e. molecular imaging). However, more specific markers than the currently used glucose analogue, fluorodeoxyglucose 18F-FDG, are needed to assess inflammation and its consequences in different pathologies. Aims of our studies are pre-clinical evaluation of new targeted probes and techniques for molecular imaging of inflammation. The imaging agents will be evaluated in experimental models of inflammation, in healthy subjects and in patients. The main hypothesis is that sensitive whole-body imaging of inflammation will enable early diagnosis, help in patient selection to particular therapy and monitor therapy outcome. Noteworthy, the development of new radiopharmaceuticals requires several years’ effort and expensive proof-of-concept and acute toxicity studies. Our research is focusing on PET tracers and to lesser extent magnetic resonance (MR) and single-photon emission computed tomography (SPECT) imaging agents.


Sort by:

Seasonal variation in the brain μ-opioid receptor availability (2021)

Journal of Neuroscience
Lihua Sun, Jing Tang, Heidi Liljenbäck, Aake Honkaniemi, Jenni Virta, Janne Isojärvi, Tomi Karjalainen, Tatu Kantonen, Pirjo Nuutila, Jarmo Hietala, Valtteri Kaasinen, Kari Kalliokoski, Jussi Hirvonen, Harry Scheinin, Semi Helin, Kim Eerola, Eriika Savontaus, Emrah Yatkin, Juha O Rinne, Anne Roivainen, Lauri Nummenmaa
(A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä)

First-in-Human Study of 68 Ga-DOTA-Siglec-9, PET Ligand Targeting Vascular Adhesion Protein 1 (2020)

Journal of Nuclear Medicine
Viitanen Riikka, Moisio Olli Antero, Lankinen Petteri, Li Xiang-Guo, Koivumäki Mikko, Suilamo Sami, Tolvanen Tuula, Taimen Kirsi, Mali Markku, Kohonen Ia, Koskivirta Ilpo, Oikonen Vesa, Virtanen Helena, Santalahti Kristiina, Autio Anu, Saraste Antti, Pirilä Laura, Nuutila Pirjo, Knuuti Juhani, Jalkanen Sirpa, Roivainen Anne
(A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä)